Arbutus Biopharma Corp Stock Today
| ABUS Stock | USD 3.28 0.03 0.91% |
PerformanceWeak
| Odds Of DistressLow
|
Arbutus Biopharma is selling for under 3.28 as of the 22nd of March 2025; that is 0.91% down since the beginning of the trading day. The stock's lowest day price was 3.26. Arbutus Biopharma has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of August 2015 | Category Healthcare | Classification Health Care |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus infection, SARS-CoV-2, and other coronaviruses in the United States. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. The company has 189.49 M outstanding shares of which 7.21 M shares are presently shorted by private and institutional investors with about 9.95 trading days to cover. More on Arbutus Biopharma Corp
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Arbutus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | MBA JD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsArbutus Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arbutus Biopharma's financial leverage. It provides some insight into what part of Arbutus Biopharma's total assets is financed by creditors.
| |||||
Arbutus Biopharma Corp (ABUS) is traded on NASDAQ Exchange in USA. It is located in 701 Veterans Circle, Warminster, PA, United States, 18974 and employs 73 people. Arbutus Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 627.22 M. Arbutus Biopharma Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 189.49 M outstanding shares of which 7.21 M shares are presently shorted by private and institutional investors with about 9.95 trading days to cover.
Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0.
Check Arbutus Biopharma Probability Of Bankruptcy
Ownership AllocationArbutus Biopharma holds a total of 189.49 Million outstanding shares. Over half of Arbutus Biopharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arbutus Ownership Details
Arbutus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 1.4 M | |
| Northern Trust Corp | 2024-12-31 | 1.3 M | |
| Fourworld Capital Management Llc | 2024-12-31 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 1.1 M | |
| Woodline Partners Lp | 2024-12-31 | 971.6 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 896.3 K | |
| Saba Capital Management, Lp | 2024-12-31 | 888 K | |
| Corbin Capital Partners Lp | 2024-12-31 | 682.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 22.6 M | |
| Whitefort Capital Management, Lp. | 1225-06-30 | 13.2 M |
Arbutus Biopharma Historical Income Statement
Arbutus Stock Against Markets
Arbutus Biopharma Corporate Management
| BA Esq | General Officer | Profile | |
| Gaston Picchio | Chief Officer | Profile | |
| Lisa Caperelli | Vice Relations | Profile | |
| David CPA | CFO Officer | Profile | |
| William Collier | CEO Pres | Profile | |
| Elizabeth Howard | Gen VP | Profile |
Already Invested in Arbutus Biopharma Corp?
The danger of trading Arbutus Biopharma Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arbutus Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arbutus Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arbutus Biopharma Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.